Role for the BRCA1 C-terminal Repeats (BRCT) Protein 53BP1 in Maintaining Genomic Stability*

Julio C. MoralesDagger , Zhenfang XiaDagger , Tao Lu§, Melissa B. AldrichDagger , Bin Wang||, Corina RosalesDagger , Rodney E. KellemsDagger , Walter N. Hittelman§**, Stephen J. ElledgeDagger Dagger §§¶¶, and Phillip B. CarpenterDagger ||||

From the Dagger  Department of Biochemistry and Molecular Biology, University of Texas Health Sciences Center, Houston, Texas 77030, the § Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston Texas 77030, and the  Verna and Mars McLean Department of Biochemistry and Molecular Biology, Dagger Dagger  Department of Molecular and Human Genetics, and §§ Howard Hughes Medical Institute, Baylor College of Medicine, Houston, Texas 77030

Received for publication, December 9, 2002, and in revised form, January 24, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

p53-binding protein-1 (53BP1) is phosphorylated in response to DNA damage and rapidly relocalizes to presumptive sites of DNA damage along with Mre11 and the phosphorylated histone 2A variant, gamma -H2AX. 53BP1 associates with the BRCA1 tumor suppressor, and knock-down experiments with small interfering RNA have revealed a role for the protein in the checkpoint response to DNA damage. By generating mice defective in m53BP1 (m53BP1tr/tr), we have created an animal model to further explore its biochemical and genetic roles in vivo. We find that m53BP1tr/tr animals are growth-retarded and show various immune deficiencies including a specific reduction in thymus size and T cell count. Consistent with a role in responding to DNA damage, we find that m53BP1tr/tr mice are sensitive to ionizing radiation (gamma -IR), and cells from these animals exhibit chromosomal abnormalities consistent with defects in DNA repair. Thus, 53BP1 is a critical element in the DNA damage response and plays an integral role in maintaining genomic stability.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

DNA damage-response mechanisms ensure the fidelity of chromosomal transmission, and their failure may lead to the development of diseases such as cancer (1). In response to gamma -IR,1 phosphoinositide-like kinases (PIKs) such as ATM (mutated in ataxia-telangiectasia) transduce damage signals to kinases, transcription factors, and DNA repair proteins by targeting (S/T)Q motifs (2). A second PIK, ATR (ATM- and Rad3-related), also responds to gamma -IR, but it appears to respond primarily to agents that create replicational stress (i.e. hydroxyurea and aphidicolin) (2). ATM and ATR have distinct but overlapping substrate specificities including the ability of both enzymes to target p53 serine residue 15 (Ser-15) as well as the product of breast cancer susceptibility gene 1, BRCA1, at Ser-1423 (3, 4). BRCA1 is a major target of the DNA damage response, and mutations in BRCA1 contribute to nearly 50% of familial forms of breast and ovarian cancer (5). BRCA1 had been found associated with RNA polymerase II (6), chromatin-remodeling factors (7), and a variety of DNA repair and replication factors (8-10). Indeed, BRCA1 has been shown to function in genomic stability by controlling homologous recombination, transcription-coupled repair of oxidative DNA damage, and cell cycle checkpoints (11-14).

One protein that contains numerous (S/T)Q motifs and two C-terminal BRCT repeats is p53-binding protein 1 (53BP1). 53BP1 was discovered as a p53-interacting factor in a two-hybrid screen (15) and was subsequently proposed to function as a transcriptional co-activator of p53 (16). Although the relationship between 53BP1 and p53 has not been fully established, 53BP1 and p53 from both Xenopus and humans have been shown to interact either directly or indirectly in experimental settings that express high levels of 53BP1 protein from plasmids or that naturally occur in eggs (15, 17). We, as well as others, have demonstrated previously that 53BP1 is involved in the DNA damage-response network (17-20). 53BP1 proteins are phosphorylated in response to gamma -IR, and this is likely governed by the action of PIKs like ATM (17, 19, 20). gamma -IR also induces 53BP1 to rapidly relocalize to DNA repair foci, and this response is delayed or inhibited by treatment with the PIK inhibitors caffeine and wortmannin. 53BP1 foci also overlap with those formed by the Mre11 complex, BRCA1, and the phosphorylated form of the histone variant H2AX (gamma -H2AX; see Refs. 18-20). As both the Mre11 complex and gamma -H2AX are believed to localize to physical sites of DNA damage (21-23) and to recruit various DNA repair factors to these sites, 53BP1 has been inferred to localize to these sites as well. This notion is further supported by the fact that gamma -H2AX recruits 53BP1 to nuclear foci and physically interacts with 53BP1 (20, 24). Recent studies have revealed a role for 53BP1 in cell cycle checkpoints (25-27) as well as in maintaining p53 levels in response to gamma -IR (27). Here we show that a 380-amino-acid region of 53BP1 that includes a recently described kinetochore-binding domain (28) is necessary for the formation of irradiation-induced foci. We further deciphered the role of 53BP1 in the DNA damage response by generating mice defective in m53BP1. We report that murine animals expressing a truncated form of m53BP1 (m53BP1tr/tr) exhibit a pleiotropic phenotype that includes growth retardation, immune deficiencies including defects in T cell maturation, sensitivity to gamma -IR, as well as increased chromosomal aberrations. Taken together, these results reveal that 53BP1 is an integral component of the DNA damage-response network and indicate that the protein plays an important role in maintaining genomic stability.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Antibodies and Indirect Immunofluorescence-- Three antibodies that recognize both the human and murine 53BP1 proteins were generated for this study. We found that our 53BP1 antibodies recognize both the murine and human proteins. Polyclonal antibodies raised against glutathione S-transferase fusion proteins encoding the first 524 amino acids of human 53BP1 (alpha 53BP1) or the last 200 residues of the protein (alpha 53BP1-C) were affinity-purified by established procedures and used as described in the text. alpha 53BP1-N is a polyclonal, anti-peptide antibody that was raised against an N-terminal sequence GVLELSQSQDVEE that is conserved between human and murine 53BP1 proteins. Polyclonal antibodies were affinity-purified by standard methods. Anti-HA antibodies were purchased from Covance, and anti-ATR antibodies were obtained from Oncogene Research Products.

Mouse Genetics and Genotyping of m53BP1tr/tr Animals-- Murine animals defective in m53BP1 (m53BP1tr/tr) were generated with a random retrovirus as described previously (29). Genomic DNA was isolated from mouse tail snips by standard methods. Insertion of VICTR54 introduces new XbaI sites into the intron preceding exon 14 of the wild-type allele. Therefore, a disrupted m53BP1 allele will be broken into multiple XbaI fragments including a 5'-proximal, 1.5-kb fragment. To detect this fragment, we PCR-amplified and labeled with 32P a probe downstream of the 5' naturally occurring XbaI site but upstream of the one introduced by VICTR54, as shown in Fig. 2A. The primers used to amplify the 700-base pair probe for Southern analysis were 5'-CTCAGCATCCATGCTGGGC-3' and 5'-TACTTAATGAGGCTAGAGCACAGC-3'. The sequences of the primers used for RT-PCR analysis were as follows: A, 5'-CCTCAGGCAGAGTGAACA-3'; B, 5'-CTCTGTGTCGTCCACGGGAGCACT-3'; C, 5'-GTGGCGATGCAAGACATGGCCA-3'; D, 5'-GCCAAGAACAGATGGAACAGCTGA-3'. Either poly(A)+ or total RNA was isolated by standard methods and used to prepare cDNA with the Superscript one-step PCR system (Invitrogen).

Immune System Analysis-- Bone marrow, thymus, and spleen tissue were analyzed in 8-week-old male and female mice. Bone marrow was flushed with Hank's balanced salt solution (Invitrogen) from two femurs per animal. Cells were counted in 3.0% acetic acid with a hemocytomter. Bone marrow cells were stained in Hank's balanced salt solution/2.0% fetal bovine serum, with Fc block, CD11b (Mac-1), Gr-1, ter119, CD19, anti-IgM, CD45R/B220, and CD43 (all from Pharmingen). Flow cytometric analysis was performed on a BD Biosciences FACScan, with CellQuest software, and appropriate negative isotype control antibodies (Pharmingen) were used in all analyses. Spleens and thymuses were excised and gently crushed through 100-µm cell strainers (Falcon) in Hank's balanced salt solution/fetal bovine serum. Red blood cells were lysed with ACK buffer (0.15 M NH4Cl, 1.0 mM KHCO3, 0.1 mM EDTA, pH 7.2) (5 ml/spleen or thymus, 5 min at room temperature). After centrifugation and washing with phosphate-buffered saline/2.0% fetal bovine serum, the cells were counted as above and stained for flow cytometric analysis. Thymic cells were stained with CD4, CD8, CD25, CD44, and CD3 (Pharmingen). Flow cytometry was performed as above.

Chromosome Aberration Studies-- Exponentially growing passage 2 MEFs were irradiated at room temperature with 0, 0.5, or 1.5 Gy of gamma -IR using a Nasatron irradiator, returned to 37 °C for 30 min to allow cells irradiated in mitosis to exit, and then incubated with 1 µg/ml colcemid for 2 h prior to cell harvest, hypotonic (0.075 M KCl) fixation (3:1 methanol:glacial acetic acid), and metaphase spread preparation. Dried slide preparations were stained with Giemsa and examined for the presence of chromatid gaps, breaks, and exchanges by light microscopy. Between 50 and 100 metaphases were scored for each treatment.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Dynamic Nuclear Localization of 53BP1 in the Absence and Presence of DNA Damage-- It has been recently shown that 53BP1 localizes to the kinetochore during mitosis (28). However, the behavior of 53BP1 during interphase in the absence of extrinsic DNA damage has not been fully investigated. To examine the interphase behavior of 53BP1 during the course of normal, unperturbed MCF-7 cell cycles, we used a laser scanning cytometer to determine the nuclear localization of 53BP1 and the cellular DNA content for any given cell. In G1, 53BP1 exists in a diffuse nuclear pattern as well as in large nuclear "dots" (Fig. 1A). In S-phase, 53BP1 can be found in a discrete, punctate pattern (Fig. 1A). The nuclear distribution pattern of 53BP1 in G2 cells appeared in two types, one similar to S-phase but with fewer foci (Fig. 1A) and one that exhibited few, if any, large dots (not shown). It is well established that 53BP1 relocalizes to nuclear foci in response to DNA damage (17-20). We found that 53BP1 and ATR co-localized to nuclear foci in response to hydroxyurea (Fig. 1B). We also found that 53BP1 physically associates with ATR in nuclear extracts derived from K562 cells (Fig. 1C). 53BP1 can be detected in ATR immunoprecipitates and ATR is present in 53BP1 immunoprecipitates, and the association occurs independently of DNA damage (Fig. 1C). Moreover, ATR phosphorylates 53BP1 in vitro (not shown). Thus, 53BP1 interacts with various factors implicated in genomic stability including ATR, p53, H2AX, BRCA1, and Chk2. To address which structural elements of 53BP1 are required for the formation of irradiation-induced foci, we created a series of mutant constructs in the 53BP1-expression vector pCMH6K53BP1 (16). We generated mutant forms of 53BP1 that deleted the C-terminal BRCT motifs (Delta BRCT), the kinetochore-binding region (Delta KINET), the N-terminal 1,234 residues except for the initiation codon (Delta NH3), and a protein mutated at 15 potential phosphorylation sites (15AQ), some of which are known to be targeted during the DNA damage response.2 All constructs maintained the nuclear localization signal. Transient tranfections with these various constructs into MCF-7 cells revealed that the mutant proteins were being expressed (not shown). We confirmed that the wild-type, HA-tagged version of 53BP1 encoded by pCMH6K53BP1 generated nuclear foci in response to DNA damage when immunostained with an antibody specific for the HA tag (Fig. 1D). Untransfected cells were found to stain negative with anti-HA antibodies (not shown). Our results indicate that the majority of 53BP1 appears dispensable for DNA damage-inducible focus formation, including the N-terminal 1,234 residues (which includes numerous (S/T)Q motifs) as well as the C-terminal BRCT motifs (Fig. 1D). Surprisingly, Delta KINET, a 380-amino-acid deletion (residues 1,236-1,615) that removes the kinetochore binding region (28) of 53BP1, failed to form irradiation-induced foci as the protein persisted in a diffuse nuclear pattern after irradiation (Fig. 1D).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   Dynamic nuclear localization of human 53BP1 during interphase, association with ATR, and structural requirements for DNA damage inducible focus formation. As shown in A, immunofluorescence analysis with an antibody specific for 53BP1 (alpha 53BP1; see "Experimental Procedures") reveals the nuclear staining pattern for cells unambiguously assigned to the G1-phase (left), S-phase (middle), and G2-phase (right) of the cell cycle as determined by DNA content with a lasing scanning cytometer. Black and white images were captured with a ×100 objective on a Zeiss Axiophot and pseudocolored in Adobe PhotoShop. As shown in B, ATR and 53BP1 co-localize to nuclear foci in response to hydroxyurea (2.0 mM). Left panel, immunostaining for 53BP1. Middle, immunostaining with an antibody specific for ATR (see "Experimental Procedures"). Right, merged images to show co-localization between 53BP1 and ATR. As shown in C, ATR and 53BP1 physically interact before and after DNA damage. K562 cells were grown and either left untreated (lanes 1 and 2) or treated with 2.0 mM hydroxyurea (HU; lane 3) for 18 h prior to the preparation of nuclear extracts for immunoprecipitation with an antibody against 53BP1 (left panel) or ATR (right panel). Immunoblotting was then performed with the reciprocal antibodies as shown. D, schematic representation of primary structure of 53BP1 (not drawn to scale). Hatched lines represent locations of (S/T)Q sites mutated in 15AQ. KINET, kinetochore-binding region (28); NLS, nuclear localization signal (28). E, identification of a region of 53BP1 required for irradiation-induced focus formation. Wild-type, HA-tagged 53BP1 and various mutant derivatives were transfected into MCF7 cells and treated with 10 Gy of ionizing radiation prior to fixation and immunostaining with an antibody specific for the HA tag (Covance). The following constructs expressing in-frame 53BP1 deletions or mutations were made: Delta BRCT (deletes amino acid residues 1,786-1,964), Delta KINET (deletes amino acid residues 1,236-1,615), Delta NH3 (deletes the first 1,234 amino acids residues except for the initiation codon), and 15AQ, a construct with mutations in 15 (S/T)Q sites. The following serine or threonine residues were mutated to alanines in 15AQ: Ser-6, Ser-13, Ser-25, Ser-29, Ser-105, Ser-166, Ser-176, Ser-178, Thr-302, Ser-452, Ser-523, Ser-543, Ser-625, Ser-784, Ser-892. All constructs were verified by DNA sequencing and expressed in either 293T or MCF7 cells (not shown).

Generation of Mice Defective in m53BP1 (m53BP1tr/tr)-- To begin to decipher the functional role for 53BP1 in the DNA damage response, we identified embryonic stem cells (OST94324) from Omnibank (29) containing a single, ~5.0-kb retroviral insertion (VICTR54; Fig. 2A) in murine 53BP1 (m53BP1; 1,957 amino acids; 80% identity to human 53BP1; see Ref. 28). VICTR54 was found inserted within a 4.9-kb intron located between exons 13 and 14 (Fig. 2A). VICTR54, and its related vectors, are usually found within introns and contain splice acceptor (SA) and donor (SD) sequences such that a neomycin (NEO) resistance gene and flanking sequences are spliced into the mature transcript as an exon (Fig. 2A) (29). These transcriptional fusions disrupt the coding sequence through the introduction of premature stop codons. Such gene trapping methodologies have been applied previously to understanding gene function (29). OST94324 cells were used to generate transgenic animals heterozygous in m53BP1 (m53BP1+/tr) as described previously (29). Southern blotting with DNA isolated from tail biopsies confirmed the disruption in m53BP1 and was used to genotype the animals (Fig. 2B; see "Experimental Procedures"). Crosses between heterozygous animals produced m53BP1tr/tr progeny born at the expected frequencies. The m53BP1tr/tr animals were found to be fertile, but we did observe that crosses between mutant animals produced smaller litters as some embryos spontaneously aborted and were reabsorbed by the mother (data not shown). RT-PCR analysis with various primers 5' and 3' to the insertion demonstrated that exon 13 failed to properly splice next to exon 14 in the m53BP1tr/tr mice (Fig. 2C). Rather, the "artificial" exon containing neomycin from VICTR54 was spliced adjacent to exon 13 as verified with primers specific for exon 13 and the neomycin gene (primer set D/A; Fig. 2C). Sequencing of a cloned RT-PCR product spanning the insertion event revealed that the natural coding sequence of m53BP1 had stopped after residue 1,205, where it then fused to 21 residues derived from VICTR54 before terminating (Fig. 2D). Therefore the disrupted allele of m53BP1 encodes a truncated 1,226 residue protein (m53BP1tr), and notably, m53BP1tr is missing over 700 residues including its functional nuclear localization signal, kinetochore binding domain (KINET), and two BRCT motifs (Fig. 2D). To determine whether m53BP1tr was expressed, we performed immunoprecipitation/Western blotting (IP/WB) analysis from brain extracts derived from m53BP1+/+, m53BP1+/tr, and m53BPtr/tr animals. By using antibodies specific for the N and C termini of 53BP1 (alpha 53BP1-N and alpha 53BP1-C, respectively; see "Experimental Procedures"), we determined that a truncated m53BP1 protein corresponding to m53BP1tr appeared in heterozygous and mutant extracts but not in wild-type ones (Fig. 2E). The levels of m53BP1tr appeared much lower than the full-length protein and, in some cases, we observed an apparent isoform of m53BP1 in wild-type and heterozygous animals (Fig. 2E). The disappearance of full-length m53BP1 in the mutant samples was accompanied by the appearance of a smaller protein corresponding to m53BP1tr (Fig. 2E). We observed that alpha 53BP1-N cross-reacted with m53BP1tr but not with alpha 53BP1-C, demonstrating that m53BP1 is indeed truncated in m53BP1tr/tr animals (Fig. 2, E and F).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   Generation and characterization of mice defective in m53BP1 (m53BP1tr/tr). A, schematic diagram of insertion event in m53BP1 (not drawn to scale). The thick horizontal lines represent positions of probes for Southern blotting as described in B. Arrows represent the position and orientation of PCR primers used in C. The insertion of VICTR54 was determined by DNA sequencing to reside within the intron preceding exon 14 at nucleotide position 1,730 (marked by *). Splicing of the neomycin gene and flanking DNA produces a transcript that potentially disrupts the proper splicing of exons 13 and 14. LTR, long-terminal repeat; NEO, neomycin resistance gene; PGK, phosphoglycerate kinase-1; BTK, Bruton's tyrosine kinase; SA and SD, splice acceptor and donor, respectively. B, top, Southern blotting to determine the genotype of m53BP1-defective animals. 10 µg of genomic DNA was digested with XbaI and was probed with a radiolabeled fragment (see "Experimental Procedures") capable of discerning wild-type (WT) and mutant alleles as discussed under "Experimental Procedures." Bottom, a 700-bp probe derived from the neomycin gene was used to help genotype the animals. +/+, wild type; +/tr, heterozygous; tr/tr, homozygous. As shown in C, RT-PCR analysis indicates that improper splicing occurs between exons 13 and 14 in m53BP1tr/tr mice. Positions and orientation of primers for PCR are indicated in A. Control reactions without reverse transcriptase showed essentially no amplified products (not shown). As shown in D, m53BP1tr/tr encodes a truncated protein of 1,226 amino acids. RT-PCR products derived from primer set A/D (as shown in C) using RNA isolated from m53BP1tr/tr animals as template were cloned into the TA vector (Invitrogen). DNA sequencing and conceptual translation indicated that m53BP1tr/tr animals potentially encode a truncated m53BP1 protein (m53BP1tr) of 1,205 natural residues along with an additional 21 residues derived from the VICTR54 vector. m53BP1tr is missing over 700 C-terminal residues, including those that specify the kinetochore binding domain (KINET; amino acids 1,220-1,601), the nuclear localization signal (NLS; mapped to amino acids 1,601-1,703; ref), and the C-terminal BRCT repeats (amino acids, 1,665-1,957). The small, vertical rectangle in m53BP1tr represents the additional vector-derived 21 residues. E and F, detection of m53BP1tr protein by IP/WB analysis. 1.0 mg of total brain protein extracts derived from +/+, +/tr, and tr/tr animals was immunoprecipitated with 5 µg of affinity-purified antibody (alpha 53BP1-N) raised against an N-terminal peptide sequence (see "Experimental Procedures") and split into two equal parts. One part (E) was blotted with alpha 53BP1-N, and the other (F) was immunoblotted with an affinity-purified antibody specific for the C terminus (alpha 53BP1-C). E, lane 1, IP from 100 µg of MCF-7 nuclear extract. Lane 2, IP with nonspecific IgG control. Lanes 3-5, IP with +/+, +/tr, and tr/tr animals as determined in B. IP/WB analysis shows the presence of m53BP1tr in m53BP1+/tr and m53BP1tr/tr animals but not of m53BP +/+ ones. In some cases, we observed an apparent isoform of m53BP1 in brain tissue, as designated by the asterisk. F, WB with alpha 53BP1-C, an affinity-purified antibody against the C-terminal 200 residues of human 53BP1. As shown, alpha 53BP1-C recognizes full-length m53BP1 but fails to immunoreact with m53BP1tr, indicating that the protein is indeed missing C-terminal residues of m53BP1.

Immune Deficiencies in m53BP1tr/tr Mice-- We observed that m53BP1tr/tr animals were growth-retarded as the males and females were found on average to weigh 25 and 15% less, respectively, than their wild-type littermates (Fig. 3A). We found that thymuses derived from m53BP1tr/tr animals were significantly smaller and possessed fewer cells than those from m53BP1+/+ animals (Fig. 3B). This suggests that defects in m53BP1 may contribute to immune deficiencies, a result that has been observed for various DNA damage-response factors, including H2AX (24). We found that the lymphoid organ architecture of thymuses, as assayed by hematoxylin and eosin staining of tissue sections, appeared normal in m53BP1tr/tr mice (data not shown). In addition, flow cytometric analysis with a variety of markers (e.g. B220, CD43, Gr-1, CD11a, and Ter119) revealed that bone marrow pro-B, pre-B, myeloid, and erythroid progenitor populations were normal in m53BP1tr/tr mice (not shown). Although CD4 and CD8 T cell populations were proportionately similar in m53BP1tr/tr and m53BP1+/+ thymuses, we observed that progression out of the DNIII stage of early thymocyte development was impaired in m53BP1tr/tr animals (Fig. 3C), the stage at which beta -gene rearrangement occurs. This indicates that m53BP1 participates in proper T cell development, a process known to require various DNA repair factors (30). We also found that spleens derived from m53BP1tr/tr animals were similar in size and organ architecture to those from m53BP1tr/tr animals and that the lack of functional m53BP1 did not affect the proportions of B and T lymphocytes (data not shown). We did observe, however, that m53BP1tr/tr spleens were deficient in mature B cells (IgMloIgDhi; Fig. 4D), suggesting that deficiencies in m53BP1 may also result in defective B lymphocyte development.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   Growth retardation and immune deficiencies in mice defective in m53BP1. A, mean body weight, in grams, of m53BP1+/+ and m53BP1tr/tr mice. (n = 10). As shown in B, reduced thymus size in m53BP1tr/tr animals results in lower tissue cell count. Mean cell numbers are × 106 (per mouse) of bone marrow (two femurs per mouse), spleens, and thymuses from m53BP1+/+ and m53BP1tr/tr mice (n = 4). C, defective T cell development in m53BP1tr/tr mice as revealed by double-negative thymocyte populations. CD4+ and CD8+ cells were removed by gating, leaving DNI (CD44+CD25-), DNII (CD44+CD25+), DNIII (CD44-CD25+), and DNIV (CD44-CD25-) thymocytes. Numbers in the histogram quadrants are average percentages for four mutant or control animals. D, defective B cell development in m53BP1tr/tr animals. Immature (IgMhiIgDlo), transitional (IgMhiIgDhi), and mature (IgDhiIgMlo) B cells in m53BP1+/+ and m53BP1tr/tr mouse spleens. Numbers in the histogram quadrants are average percentages for four mutant or control mice.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Characterization of animals and cells defective in m53BP1tr/tr. A, survival of 4-6-week-old m53BP1tr/tr and m53BP1+/+ mice after exposure to 7 Gy of gamma -IR. Six animals from each genotype were used in the experiment. B, survival of 4-6-week-old m53BP1tr/tr animals after exposure to 1.5 Gy of ionizing radiation.

Genomic Instability in m53BP1tr/tr Mice-- Mice with defects in double-stranded break repair are highly sensitive to gamma -IR. To evaluate whether m53BP1 contributes to increased sensitivity to DNA damage, we treated m53BP1tr/tr or wild-type animals with 7 Gy of gamma -IR. After this whole body irradiation treatment, we found that 100% of the mutant animals died between 9 and 15 days post-irradiation in contrast to only 16% of the control littermates (Fig. 4A). This shows that animals defective in m53BP1 are highly sensitive to gamma -IR, a result that parallels previous observations with H2AX-deficient mice (24). Despite this, we found that m53BP1tr/tr animals treated with lower doses of gamma -IR (1.5 Gy) remained viable (Fig. 4B). To further explore m53BP1 function, we generated embryonic fibroblasts (MEFs) from wild-type and m53BP1tr/tr animals. m53BP1tr/tr MEFs proliferated more slowly than their wild-type counterparts (Fig. 5A). Immunofluorescence analysis indicated that the truncated m53BP1 protein expressed in m53BP1tr/tr animals failed to form foci in response to DNA damage as it was essentially absent from the nucleus (data not shown). This result is consistent with our transfection studies, which have shown that C-terminal determinants (Delta KINET) are necessary for focus formation. The relative growth of the mutant and the wild-type MEFs was reminiscent of what has been recently described for H2AX (24). To further characterize cells defective in m53BP1, we examined the cytological consequences of impaired m53BP1 function in early passage MEFs derived from m53BP1tr/tr and m53BP1+/+ animals. For this, exponentially growing MEFs (passage 2) were treated with 0, 0.5, or 1.5 Gy of gamma -IR, and metaphase preparations were examined 2.5 h post-irradiation. Untreated MEFs derived from m53BP1tr/tr animals showed increased levels of chromatid gaps, breaks, and, to a lesser extent, exchanges when compared with those derived from m53BP1+/+ mice, suggesting an intrinsic genomic stability defect in the mutant cells (Fig. 5, B and C). More strikingly, irradiated MEFs derived from m53BP1tr/tr animals showed an ~2-fold increase in levels of chromatid breaks and gaps when compared with MEFs derived from wild-type mice (Fig. 5, B and C). Although MEFS from m53BP1tr/tr animals showed relatively high chromatid exchange rates at 0.5 Gy when compared with those from m53BP1+/+ animals, this difference was less apparent at 1.5 Gy, perhaps due to the limited progression to mitosis of the most damaged cells from both populations during this time frame. One possible explanation for the increased frequencies of chromosomal aberrations observed in the m53BP1tr/tr MEFs following irradiation might be a deficiency in a G2 checkpoint response whereby more damaged cells would still be permitted to enter mitosis and would be available for chromosome analysis. In fact, recent reports have implicated 53BP1 in the G2/M checkpoint (25-27). To examine this in our MEFs, either m53BP1tr/tr or wild-type MEFs were treated with 0, 1.5, or 10 Gy of gamma -IR, and cultures were analyzed for the fraction of cells showing phospho-histone H3 immunostaining (mitotic cells) either after 1 or 16 h post-irradiation (in the presence of colcemid). Although all cell types showed evidence of a partial G2/M block following irradiation, MEFs derived from m53BP1tr/tr mice showed only a slight decrease, if any, in the G2 block when compared with MEFs derived from wild-type mice (data not shown). The minimal effects on the G2/M checkpoint observed in our m53BP1tr/tr MEFs may be due to the nature of the truncated protein produced from the m53BP1tr/tr allele that is expressed in our mutant animals described here.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Chromosomal abnormalities in m53BP1tr/tr cells. A, growth curve of MEFs derived from m53BP1tr/tr (open diamonds) and m53BP1+/+ (closed circles). B, metaphase preparation of mutant MEF following 1.5 Gy of gamma -IR. Note the presence of a chromatid gap, two chromatid breaks, and one chromatid exchange in the metaphase sample. C, relative frequencies of chromatid gaps, breaks, and exchanges in metaphases of wild-type and mutant MEFs following 0, 0.5, and 1.5 Gy of ionizing radiation.

53BP1 interacts with a variety of factors known to be involved in the maintenance of genomic stability including ATR, p53, H2AX, BRCA1, Chk2, and ATM (15, 20, 25, 27). The generation of murine animals defective in m53BP1 provides a valuable tool to further understand the role of the protein in the DNA damage response. The m53BP1tr/tr allele expresses a truncated version of m53BP1, and this likely represents a significant impairment in some aspects of its function. m53BP1tr/tr is missing over 700 amino acids including the nuclear localization signal, the C-terminal BRCT motifs, and a kinetochore-binding domain. We have observed that this domain is also necessary for forming irradiation-induced nuclear foci. Indeed, the lack of detectable, irradiation-induced foci in mutant MEFs suggests that the protein cannot fully perform its functions as a DNA damage-response element. Moreover, the lethality observed for m53BP1tr/tr mice at higher doses of radiation (7 Gy) suggests that there are no other factors acting redundantly with m53BP1 with respect to this aspect of radiation resistance and indicates that m53BP1 is a critical element for double-stranded break repair. Therefore, the C-terminal 700 amino acids of m53BP1 encode important, functional determinants of the protein.

We observed that m53BP1tr/tr animals are growth-retarded as the males weigh, on average, 25% less than their wild-type littermates. The decreased thymus size, reduced T cell count, immature B cell population, and lack of progression out of DNIII for thymus T cells reveal that m53BP1tr/tr animals are immune-deficient. How m53BP1 contributes to this process remains to be established, but one possibility is that the protein participates in the maturation of T-cell receptors and immunoglobulins during V(D)J recombination, a process known to utilize DNA repair proteins (30). This is particularly interesting given the involvement of m53BP1 in double-stranded break repair as revealed by several factors including, most notably, the sensitivity of m53BP1tr/tr animals after exposure to 7 Gy of ionizing radiation. Indeed, sensitivity to ionizing radiation often correlates with impaired V(D)J joining (30). Moreover, H2AX defective-animals are also immune-deficient (24). As H2AX is required for the formation of 53BP1 foci and because it physically associates with 53BP1 (20), it is possible that an ordered pathway of assembly of DNA damage-response proteins at these programmed breaks may facilitate V(D)J recombination and maximize antibody diversity.

Our results show that genetic defects in m53BP1 result in a pleiotropic phenotype consistent with defects in DNA repair and checkpoint control. The phenotype of 53BP1-defective animals is quite similar to H2AX-deficient ones, consistent with the notion that H2AX operates upstream of 53BP1 in a DNA damage-response pathway. When such pathways are defective, cells cannot properly repair damaged DNA, a situation that may lead to increased genomic instability and the development of diseases such as cancer. For example, given the immune deficiencies in m53BP1tr/tr mice, one may anticipate the generation of lymphomas. In light of this, we have not observed the development of any cancerous phenotypes in our m53BP1-defective mice. Although there are a variety of possible reasons for this (i.e. genetic background, allele, etc.), it is interesting to note that mice nullizygous for H2AX also apparently fail to generate cancers.3 As H2AX and 53BP1 are not required for viability, it is possible that mutations in 53BP1, when combined with other mutations in critical DNA damage-response elements (i.e. H2AX, ATM, and p53) will lead to more severe defects in genomic stability, a process that may then lead to the development of cancer. The analysis of cells derived from these crosses is likely to provide more insight into how 53BP1 functions in the DNA damage response in concert with its various interacting partners.

    ACKNOWLEDGEMENTS

We thank Jian Kuang and Randy Legerski for help in setting up our makeshift laboratory at M. D. Anderson in the aftermath of Hurricane Allison. We thank Heladio Ibarguen for help with the metaphase spreads. We are grateful to David Cortez for providing useful suggestions during the course of the project. We are also indebted to Mike Blackburn, Rob Kirken, Jeff Frost, Hays Young, and Jose Molina for technical advice. We thank Jungie Chen for communicating results prior to publication.

    FOOTNOTES

* This work was supported by grants from The Robert A. Welch Foundation (to P. B. C.) and The Ellison Medical Foundation (to P. B. C.) as well as National Institute of Health Grants GM65812-01 (to P. B. C.), DK46207 (to R. E. K.), and 5P30 CA16672 (to W. N. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| A fellow of the U. S. Army Breast Cancer Postdoctoral Trainee Award.

** A Sophie Caroline Steves Distinguished Professor in Cancer Research.

¶¶ An investigator with the Howard Hughes Medical Institute, an Ellison Medical Foundation Senior Scholar, and the Welch Professor of Biochemistry.

|||| An Ellison Medical Foundation Junior Scholar who is grateful for their support. To whom correspondence should be addressed. Fax: 713-500-0652; E-mail: Phillip.B.Carpenter@uth.tmc.edu.

Published, JBC Papers in Press, February 10, 2003, DOI 10.1074/jbc.M212484200

2 Z. Xia, J. C. Morales, and P. B. Carpenter, unpublished data.

3 Dr. A. Nussenzweig, personal communication.

    ABBREVIATIONS

The abbreviations used are: gamma -IR, ionizing radiation; PIK, phosphatidyl inositol-like kinase; BRCT, BRCA1 C-terminal repeats; MEF, murine embryonic fibroblast; ATM, mutated in ataxia-telangiectasia; ATR, ATM- and Rad3-related; RT, reverse transcription; HA, hemagglutinin; IP, immunoprecipitation; WB, Western blotting; DN, double negative.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Zhou, B. S., and Elledge, S. J. (2000) Nature 408, 433-439[CrossRef][Medline] [Order article via Infotrieve]
2. Abraham, R. T. (2001) Genes Dev. 15, 2177-2196[Free Full Text]
3. Cortez, D., Wang, Y., Qin, J., and Elledge, S. J. (1999) Science 286, 1162-1166[Abstract/Free Full Text]
4. Tibbetts, R. S., Mrumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S.-Y., Taya, Y., Prives, C., and Abraham, R. T. (1999) Genes Dev. 13, 152-157[Abstract/Free Full Text]
5. Scully, R., and Livingston, D. (2000) Nature 408, 429-432[CrossRef][Medline] [Order article via Infotrieve]
6. Scully, R., Anderson, S. F., Chao, D., Wei, M., Ye, W., Young, R. A., Livingston, D. M., and Parvin, J. D. (1997a) Proc. Natl. Acad. Sci. U. S. A. 94, 5605-5610[Abstract/Free Full Text]
7. Bochar, D. A., Wang, L., Beniya, H., Kinev, A., Xue, Y., Lane, W. S., Wang, W., Kashanchi, F., and Shiekhattar, R. (2000) Cell 102, 257-265[Medline] [Order article via Infotrieve]
8. Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., and Livingston, D. M. (1997b) Cell 88, 265-275[Medline] [Order article via Infotrieve]
9. Chen, J., Silver, D. P., Walpita, D., Cantor, S. B., Gazdar, A. F., Tomlinson, G., Couch, F. J., Weber, B. L., Ashley, T., Livingston, D. M., and Scully, R. (1998) Mol. Cell 2, 317-328[Medline] [Order article via Infotrieve]
10. Wang, Y., Cortez, D., Yazdi, P., Neff, N., Elledge, S. J., and Qin, J. (2000) Genes Dev. 14, 927-939[Abstract/Free Full Text]
11. Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., and Leadon, S. A. (1998) Science 281, 1009-1012[Abstract/Free Full Text]
12. Moynahan, M. E., Chiu, J. W., Koller, B. H., and Jasin, M. (1999) Mol. Cell 4, 511-518[Medline] [Order article via Infotrieve]
13. Xu, X., Weave, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W., Harris, C. C., Ried, T., and Deng, C. X. (1999) Mol. Cell 3, 389-395[Medline] [Order article via Infotrieve]
14. Xu, B., Kim, S.-T., and Kastan, M. B. (2001) Mol. Cell Biol. 21, 3445-3450[Abstract/Free Full Text]
15. Iwabuchi, K., Bartel, P. L., Li, B., Maraaccino, R., and Fields, S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6098-6102[Abstract]
16. Iwabuchi, K., Li, B., Massa, H. F., Trask, B. J., Date, T., and Fields, S. (1998) J. Biol. Chem. 273, 26061-26068[Abstract/Free Full Text]
17. Xia, Z., Morales, J. C., Dunphy, W. G., and Carpenter, P. B. (2001) J. Biol. Chem. 276, 2708-2718[Abstract/Free Full Text]
18. Schultz, L. B., Chehab, N. H., Malikzay, A., and Halazonetis, T. (2000) J. Cell Biol. 151, 1381-1390[Abstract/Free Full Text]
19. Anderson, L., Henderson, C., and Adachi, Y. (2001) Mol. Cell. Biol. 21, 1719-1729[Abstract/Free Full Text]
20. Rappold, I., Iwabuchi, K., Date, T., and Chen, J. (2001) J. Cell Biol. 153, 613-620[Abstract/Free Full Text]
21. Nelms, B. E., Maser, R. S., MacKay, J. F., Lagally, M. G., and Petrini, J. H. (1998) Science 280, 590-592[Abstract/Free Full Text]
22. Rogakou, E. P., Boon, C., Redon, C., and Bonner, W. M. (1999) J. Cell Biol. 146, 905-916[Abstract/Free Full Text]
23. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., and Bonner, W. M. (1998) J. Biol. Chem. 273, 5858-5868[Abstract/Free Full Text]
24. Celeste, A., Petersen, S., Romanienko, P. J., Fernandez-Capetillo, O., Chen, H. T., Sedelnikova, O. A., Reina-San Martin, B., Coppola, V., Meffre, E., Difilippantonio, M. J., Redon, C., Pilch, D. R., Olaru, A., Eckhaus, M., Camerini-Otero, R. D., Tessarollo, L., Livak, F., Manova, K., Bonner, W. M., Nussenzweig, M. C., and Nussenzweig, A. (2002) Science 296, 922-927[Abstract/Free Full Text]
25. DiTullio, R. A., Mochan, T. A., Venere, M., Bartkova, J., Sehested, M., Bartek, J., and Halazonetis, T. D. (2002) Nature Cell Biol. 12, 998-1002[CrossRef]
26. Fernandez-Capetillo, O., Chen, H. T., Celeste, A., Ward, I., Romamienko, P. J., Morales, J. C., Naka, K., Xia, Z., Camerini-Otero, R. D., Motoyama, N., Carpenter, P. B., Bonner, W. M., Chen, J., and Nussenzweig, A. (2002) Nature Cell Biol. 12, 993-997[CrossRef]
27. Wang, B., Matsuoka, S., Carpenter, P. B., and Elledge, S. J. (2002) Science 298, 1435-1438[Abstract/Free Full Text]
28. Jullien, D., Vagnarelli, P., Earnshaw, W. C., and Adachi, Y. (2002) J. Cell Sci. 115, 71-79[Abstract/Free Full Text]
29. Zambrowicz, B. P., Friedrich, G. A., Buxton, E. C., Lilleberg, S. L., Person, C., and Sands, A. T. (1998) Nature 392, 608-611[CrossRef][Medline] [Order article via Infotrieve]
30. Gellert, M. (2002) Annu. Rev. Biochem. 71, 101-113[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.